Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2 BATs in Breast Cancer Leptomeningeal Metastases
NCT03661424Phase 1Terminated
- Sponsor
- University of Virginia
- Start
- Feb 2019
- Primary completion
- Dec 2021
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HER2Bi-armed activated T cells in breast cancer, sponsored by University of Virginia. Primary endpoints: Types, Frequency, Severity, Timing, Duration, and Relationship of Adverse Events and Number of participants achieving at least 80% of the planned HER2 BATs dose. Started Feb 2019; status: terminated.
02
Drugs
HER2Bi-armed activated T cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03661424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661424.